Chemical Modification of the Multitarget Neuroprotective

Compound Fisetin
Chandramouli Chiruta, David Schubert, Richard Dargusch, and Pamela Maher*
The Salk Institute for Biological Studies, 10010 N. Torrey Pines Road, La Jolla, California 92037,
United States
J. Med. Chem., 2012, 55 (1), pp 378389
DOI: 10.1021/jm2012563
Publication Date (Web): December 20, 2011
Copyright 2011 American Chemical Society

Comparison of Electrochemical Oxidation of Flavonols and Calculated Proton Affinity

and Electron Transfer Enthalpy in Water

1. Sina Kummer1,
2. Wolfgang Ruth1,
3. Oliver Khn2 and
4. Udo Kragl1,*

Version of Record online: 3 APR 2014

DOI: 10.1002/elan.201300631

2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

Issue

Electroanalysis

Volume 26, Issue 5, pages 910918, May 2014

J Med Chem. 1995 Jul 7;38(14):2794-7.

Synthesis and pharmacological evaluation of 2'-
hydroxychalcones and flavones as inhibitors of inflammatory
mediators generation.
Ballesteros JF1, Sanz MJ, Ubeda A, Miranda MA, Iborra S, Pay M, Alcaraz MJ.

A new synthesis of flavonols

J. E. Gowan, P. M. Hayden and T. S. Wheeler

J. Chem. Soc., 1955, 862-866

DOI: 10.1039/JR9550000862

Synthesis of highly functionalized flavones and

chromones using cycloacylation reactions and C-3
functionalization. A total synthesis of hormothamnione
Lynda W. McGarry, Michael R. Detty
J. Org. Chem., 1990, 55 (14), pp 43494356
DOI: 10.1021/jo00301a027
Publication Date: July 1990

A Practical and Economical High-Yielding, Six-Step

Sequence Synthesis of a Flavone: Application to the
Multigram-Scale Synthesis of Ladanein
Xavier Martin-Benlloch, Mourad Elhabiri, Don Antoine Lanfranchi, and Elisabeth Davioud-
Charvet*
Laboratory of Bioorganic and Medicinal Chemistry, UMR7509 CNRS-University of Strasbourg,
European School of Chemistry, Polymers and Materials (ECPM), 25 Rue Becquerel, F-67087
Strasbourg, France
Org. Process Res. Dev., 2014, 18 (5), pp 613617
DOI: 10.1021/op4003642
Publication Date (Web): April 10, 2014
Copyright 2014 American Chemical Society
Novel Quercetin Glycosides as Potent Anti-MRSA and Anti-VRE
Agents

Author(s): Abugafar M.L. Hossion, Kenji Sasaki.

Abstract:

Each year in the United States, at least 2 million people become infected with bacteria that
are resistant to antibiotics and at least 23,000 people die each year as a direct result of
these infections (Threat report 2013). Vancomycin is an FDA approved antibiotic and is
growing importance in the treatment of hospital infections, with particular emphasis on its
value to fight against methicillin-resistant Staphylococcus aureus (MRSA). The increasing
use of vancomycin to treat infections caused by the Gram-positive MRSA in the 1970s
selected for drug-resistant enterococci, less potent than staphylococci but opportunistic in
the space vacated by other bacteria and in patients with compromised immune systems.
The dramatic rise of antibiotic-resistant bacteria over the past two decades has stressed the
need for completely novel classes of antibacterial agents. This paper reports the recent
patent review on the strategy for finding novel quercetinglycoside type antibacterial agents
against vancomycin-resistant bacterial strains.